Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wi-Fi Failures, Custom Tech And Other Challenges Of Bringing Specialty Care Into Patients’ Homes

Executive Summary

The CEOs Reimagine Care, Cortica and Inbound Health, part of the rising trend to bring specialty and acute care programs into the home, joined a panel at the DHIS West conference to discuss their views on the future of virtual and at-home delivery of complex care and shared some of their own challenges they encountered. 

You may also be interested in...



Siemens Healthineers, GE HealthCare Race To Develop Next-Gen AI Solutions For Personalized Care

Siemens Healthineers and GE HealthCare are among industry leaders blazing a trail to a digitally connected, AI-powered healthcare future.

Theradaptive Receives $7.4M From DoD, Advances Human Trials With ‘Paint-Like’ Regenerative Therapeutic

Theradaptive will use the new DoD funding to move its technology for healing bones and tissues into first human trials.

News We're Watching: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients

This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel